详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [2]Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [3]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [4]State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, People's Republic of China.

出处：

DOI：

ISSN：

关键词： breast cancer stem cell epithelial-mesenchymal transition HER2-positive cancer therapeutic approaches trastuzumab resistance

摘要：

Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of patients with the HER2-positive subtype of breast cancer. However, 50% of patients with HER2 amplification relapse due to trastuzumab resistance. Accumulating evidence indicates that breast cancer is driven by a small subset of cancer-initiating cells or breast cancer stem cells (BCSCs), which have the capacity to self-renew and differentiate to regenerate the tumor cell hierarchy. Increasing data suggest that BCSCs are resistant to conventional therapy, including chemotherapy, radiotherapy, and endocrine therapy, which drives distant metastasis and breast cancer relapse. In recent years, the trastuzumab resistance of breast cancer has been closely related to the prevalence of BCSCs. Here, our primary focus is to discuss the role of epithelial-mesenchymal transition (EMT) of BCSCs in the setting of trastuzumab resistance and approaches of reducing or eradicating BCSCs in HER2-positive breast cancer. © 2021 AlphaMed Press.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区生物工程与应用微生物 2 区肿瘤学 2 区细胞生物学 2 区血液学 3 区细胞与组织工程

最新[2023]版：

大类 | 2 区医学

小类 | 2 区生物工程与应用微生物 2 区血液学 3 区细胞与组织工程 3 区细胞生物学 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

通讯作者：

通讯机构： [4]State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, People's Republic of China. [*1]State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University,Chengdu 610041, Sichuan, People's Republic of China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer.

文献详情

相关文献